This research is Trending!
Statin discontinuation in older adults: changing the conversation, not the default
Key result
Randomised data to guide treatment decision making regarding statin discontinuation in older adults for primary prevention of cardiovascular disease remain remarkably scarce.
Why the study?
Does continuing statin treatment still make sense for older adults in their late seventies on primary prevention?
Structured PICO
Does continuing statin treatment still make sense for older adults in their late seventies on primary prevention?
P
Population
Older adults (late seventies) taking statins for primary prevention of cardiovascular disease
I
Intervention
Statin discontinuation
Ask about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The study is substantially statistically underpowered, with too small sample size and short follow-up duration, and should not be used to inform clinical decision-making. Statin treatment is widely prescribed to reduce heart attacks and strokes. In addition to the above limitations, the emphasis on all-cause mortality in the study, rather than major cardiovascular disease events, is unhelpful.”
“Firstly, the study was too small and follow-up was too short to get a clear idea of the benefits of statin treatment. Studies looking at any benefits of cholesterol treatment on life expectancy need to include many thousands of people whereas this study only included just over one thousand people and there were only 521 people in the group that were asked to stop their statin, with only 388 of these actually completing 3 years of follow-up.”
BWBryan WilliamsChief Scientific and Medical Officer, British Heart Foundation
“While the trial suggests that stopping statins may not lead to worse outcomes than continuing them over three years in this population of very elderly adults, the study findings should not be interpreted as evidence that statins are no longer beneficial. On the contrary, for the many millions of patients taking statins in the UK, they are life saving medications.”
Implication
Highlights the scarcity of randomized data to guide the common clinical decision of whether to discontinue statin therapy in older adults for primary prevention.
Abstract
Few questions in preventive cardiology are more common, or more difficult to address, than deciding when preventive therapy should be stopped. For adults who reach their late seventies after years of successful statin treatment, the clinical question is rarely whether therapy should have been started. The question instead is whether continuing statin treatment still makes sense. Despite millions of older adults taking statins for primary prevention of cardiovascular disease, randomised data to guide treatment decision making have been remarkably scarce.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Nezhad et al. (2026) conducted an editorial in Cardiovascular disease (primary prevention). Statin discontinuation was evaluated. Randomised data to guide treatment decision making regarding statin discontinuation in older adults for primary prevention of cardiovascular disease remain remarkably scarce.